| Dr Madelyn B Lipman, MD | |
|
9897 Hagen Ranch Rd, Boynton Beach, FL 33472-7400 | |
| (561) 364-4447 | |
| (561) 364-7775 |
| Full Name | Dr Madelyn B Lipman |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 47 Years |
| Location | 9897 Hagen Ranch Rd, Boynton Beach, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659358521 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207NS0135X | Dermatology - Procedural Dermatology | ME0038209 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Siperstein Dermatology Group Pllc | 3476683145 | 15 |
News Archive
Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.
An internationally recognized melanoma researcher at Moffitt Cancer Center and colleagues at the University of Kiel in Germany, including Axel Hauschild, M.D. and Katharina C. K-hler, M.D., have published an article in the current issue of The Journal of Clinical Oncology that describes immune-related adverse events for patients receiving either tremelimumab or ipilimumab, the latter a drug approved last year by the U.S. Food and Drug Administration for treating metastatic melanoma and other cancers.
NeuroSigma, Inc., a Los Angeles-based medical device company, today announced the formation of a majority owned subsidiary, NSVascular, Inc. and the signing of an exclusive license with the University of California, Los Angeles (UCLA) covering its medical applications of Thin-Film Nitinol (TFN) technology. Nitinol is a superelastic nickel and titanium alloy with unique properties that allow deformation and subsequent full recovery of the original shape upon exposure to body heat.
Scientists from Cancer Research UK have taken advantage of the selfish behaviour of cancer cells to target them with a genetically engineered virus.
Valeant Pharmaceuticals International today announced that Oxsoralen-Ultra, its therapy for severe psoriasis, is now available again in the United States on a limited supply basis.
› Verified 5 days ago
| Entity Name | Siperstein Dermatology Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609101278 PECOS PAC ID: 3476683145 Enrollment ID: O20100608000229 |
News Archive
Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.
An internationally recognized melanoma researcher at Moffitt Cancer Center and colleagues at the University of Kiel in Germany, including Axel Hauschild, M.D. and Katharina C. K-hler, M.D., have published an article in the current issue of The Journal of Clinical Oncology that describes immune-related adverse events for patients receiving either tremelimumab or ipilimumab, the latter a drug approved last year by the U.S. Food and Drug Administration for treating metastatic melanoma and other cancers.
NeuroSigma, Inc., a Los Angeles-based medical device company, today announced the formation of a majority owned subsidiary, NSVascular, Inc. and the signing of an exclusive license with the University of California, Los Angeles (UCLA) covering its medical applications of Thin-Film Nitinol (TFN) technology. Nitinol is a superelastic nickel and titanium alloy with unique properties that allow deformation and subsequent full recovery of the original shape upon exposure to body heat.
Scientists from Cancer Research UK have taken advantage of the selfish behaviour of cancer cells to target them with a genetically engineered virus.
Valeant Pharmaceuticals International today announced that Oxsoralen-Ultra, its therapy for severe psoriasis, is now available again in the United States on a limited supply basis.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Madelyn B Lipman, MD 9897 Hagen Ranch Rd, Boynton Beach, FL 33472-7400 Ph: (561) 364-7774 | Dr Madelyn B Lipman, MD 9897 Hagen Ranch Rd, Boynton Beach, FL 33472-7400 Ph: (561) 364-4447 |
News Archive
Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.
An internationally recognized melanoma researcher at Moffitt Cancer Center and colleagues at the University of Kiel in Germany, including Axel Hauschild, M.D. and Katharina C. K-hler, M.D., have published an article in the current issue of The Journal of Clinical Oncology that describes immune-related adverse events for patients receiving either tremelimumab or ipilimumab, the latter a drug approved last year by the U.S. Food and Drug Administration for treating metastatic melanoma and other cancers.
NeuroSigma, Inc., a Los Angeles-based medical device company, today announced the formation of a majority owned subsidiary, NSVascular, Inc. and the signing of an exclusive license with the University of California, Los Angeles (UCLA) covering its medical applications of Thin-Film Nitinol (TFN) technology. Nitinol is a superelastic nickel and titanium alloy with unique properties that allow deformation and subsequent full recovery of the original shape upon exposure to body heat.
Scientists from Cancer Research UK have taken advantage of the selfish behaviour of cancer cells to target them with a genetically engineered virus.
Valeant Pharmaceuticals International today announced that Oxsoralen-Ultra, its therapy for severe psoriasis, is now available again in the United States on a limited supply basis.
› Verified 5 days ago
Dr. Julian Mackay-wiggan, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9897 Hagen Ranch Rd, Boynton Beach, FL 33472 Phone: 561-364-7774 Fax: 561-364-7775 | |
Dr. Robyn Dale Siperstein, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9897 Hagen Ranch Road, Boynton Beach, FL 33472 Phone: 561-364-7774 Fax: 561-364-7775 | |
Dr. Laju M Mathew, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9897 Hagen Ranch Rd, Boynton Beach, FL 33437 Phone: 561-364-7774 | |
Ellis J Gottesfeld, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 7730 Boynton Beach Blvd, #4, Boynton Beach, FL 33437 Phone: 561-572-0299 Fax: 561-572-2596 | |
Michael Ian Shiman, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 10075 S Jog Rd, Ste 306, Boynton Beach, FL 33437 Phone: 561-424-7546 Fax: 561-244-6133 | |
Dr. Frances S Rotter, MD Dermatology Medicare: Medicare Enrolled Practice Location: 715 W Boynton Beach Blvd Ste C, Boynton Beach, FL 33426 Phone: 561-737-8376 Fax: 561-509-7068 | |
Dr. Amelia G Damse, D.O., M.P.H. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 10151 Enterprise Ctr Ste 204, Boynton Beach, FL 33437 Phone: 561-405-3000 Fax: 561-459-1444 |